MetaCap

Estrella Immunopharma (ESLA) vs Metagenomi Therapeutics (MGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Metagenomi Therapeutics (MGX) has outperformed Estrella Immunopharma (ESLA) over the past year, losing 62.6% versus a loss of 78.9%. Metagenomi Therapeutics is the larger company by market cap ($21.4 million vs $14.1 million), about 1.5 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ESLA-78.88%MGX-62.58%
+45%-20%-85%
Nov 21, 20251 yearNov 20, 2026
ESLA-72.33%MGX-94.52%
+165%+29%-107%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ESLA versus MGX key metrics
MetricESLAMGX
Share price$0.321$0.565
Market cap$14.11M$21.36M
1-day change-5.70%-7.95%
YTD return-79.42%-65.12%
1-year return-78.88%-62.58%
5-year return-96.78%—
EPS (TTM)$-0.29$-2.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$25.21M
Revenue growth (YoY)—-51.79%
Net income (latest FY)$-13.06M$-87.87M
Operating margin—-380.85%
Net margin—-348.54%
52-week high$2.27$1.87
52-week low$0.24$0.562
Distance from 52-week high-85.86%-69.79%
Analyst consensusnonestrong_buy
Avg. price target upside+3638.32%+1138.94%
Average volume2.04M163.21K
Shares outstanding43.97M37.81M
Employees—113
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MGX has outperformed ESLA by 16.3 percentage points over the past year.

About Estrella Immunopharma

ESLA stock →

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

About Metagenomi Therapeutics

MGX stock →

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees

ESLA vs MGX FAQ

Which is bigger, Estrella Immunopharma or Metagenomi Therapeutics?

Metagenomi Therapeutics (MGX) is larger, with a market capitalization of $21.36M compared with $14.11M for Estrella Immunopharma (ESLA).

Which stock has performed better over the past year, ESLA or MGX?

MGX returned -62.58% over the past 12 months, compared with -78.88% for ESLA (price return, excluding dividends). Past performance does not predict future results.

Are Estrella Immunopharma and Metagenomi Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons